Showing 1 - 5 results of 5 for search 'Jee Hung Kim', query time: 0.02s Refine Results
  1. 1
    Clinical relevance of clinical treatment score post-5 years (CTS5) in HR-positive, HER2-positive breast cancer

    Clinical relevance of clinical treatment score post-5 years (CTS5) in HR-positive, HER2-positive breast cancer by Soong June Bae, Sohyun Moon, Yoonwon Kook, Seung Ho Baek, Minji Lee, Jee Hung Kim, Sung Gwe Ahn, Joon Jeong

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative

    Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative by Su-Jin Shin, Inho Park, Heounjeong Go, Jiwon Ko, Yangkyu Lee, Jee Hung Kim, Sung Gwe Ahn, Joon Jeong, Soong June Bae, Yoon Jin Cha

    Published 2024-11-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Prevalence of germline BRCA1/2 pathogenic variants in unselected Korean patients with HER2-negative metastatic breast cancer: a nationwide prospective study (KCSG BR19-10)Research in context

    Prevalence of germline BRCA1/2 pathogenic variants in unselected Korean patients with HER2-negative metastatic breast cancer: a nationwide prospective study (KCSG BR19-10)Research... by Hee Kyung Ahn, Jee Hung Kim, Su-Jin Koh, Joohyuk Sohn, Myoung Joo Kang, Kyung Hae Jung, Kyoung Eun Lee, Jieun Lee, Sung Ae Koh, Yee Soo Chae, Jae Ho Byun, In Hae Park, Hee-Jun Kim, Jee Hyun Kim, Han Jo Kim, Joo Young Jung, Jung Lim Lee, Yoon Young Cho, Kyong Hwa Park, Ji-Yeon Kim, Seock-Ah Im, Yeon Hee Park

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (−) metastatic breast cancer patients in Korea (KCSG BR21-15)

    Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (−) metastatic breast cancer patients in Korea (KCSG BR21-15) by Jieun Lee, Dae-Won Lee, Min Hwan Kim, Jee Hung Kim, Ju Won Kim, Jae-Ho Byun, Kyoung Eun Lee, Myoung Joo Kang, Su-Jin Koh, Soojung Hong, Hye Sung Won, Han Jo Kim, In Hae Park, Seong Hoon Shin, Sun Kyung Baek, Seul-Gi Kim, Sung Ae Koh, Joo Young Jung, Ji-Yeon Kim, Gun Min Kim, Kabsoo Shin, In Sook Woo, Hyun Seon Kim, Seock-Ah Im, Yeon Hee Park

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)

    Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative... by Jieun Lee, Hee Kyung Ahn, Kyung-Hun Lee, Kyung Hae Jung, Yeon Hee Park, Sung Hoon Sim, Min Hwan Kim, Jee Hyun Kim, Jee Hung Kim, Kyoung Eun Lee, Kyong Hwa Park, Jihong Bae, Moon Hee Lee, Seungtaek Lim, Han Jo Kim, Dae-Won Lee, Jae Ho Jeong, Ji-Yeon Kim, Jin Seok Ahn, Keun Seok Lee, Joohyuk Sohn, Koung Jin Suh, Yoon Jin Cha, Kabsoo Shin, Sung-Bae Kim, Heejung Chae, Gun Min Kim, Seock-Ah Im, In Hae Park, Korean Cancer Study Group (KCSG) Breast Cancer Committee

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: